Scholar Rock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Scholar Rock 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRRK

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. 

CEO
David L. Hallal
CEODavid L. Hallal
Employees
289
Employees289
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2012
Founded2012
Employees
289
Employees289

SRRK Key Statistics

Market cap
5.69B
Market cap5.69B
Price-Earnings ratio
-14.35
Price-Earnings ratio-14.35
Dividend yield
Dividend yield
Average volume
2.26M
Average volume2.26M
High today
$50.00
High today$50.00
Low today
$48.44
Low today$48.44
Open price
$49.88
Open price$49.88
Volume
382.49K
Volume382.49K
52 Week high
$50.50
52 Week high$50.50
52 Week low
$22.71
52 Week low$22.71

Stock Snapshot

The current Scholar Rock(SRRK) stock price is $49.53, with a market capitalization of 5.69B. The stock trades at a price-to-earnings (P/E) ratio of -14.35.

On 2026-04-01, Scholar Rock(SRRK) stock moved within a range of $48.44 to $50.00. With shares now at $49.53, the stock is trading +2.3% above its intraday low and -0.9% below the session's peak.

Trading volume for Scholar Rock(SRRK) stock has reached 382.49K, versus its average volume of 2.26M.

The stock's 52-week range extends from a low of $22.71 to a high of $50.50.

The stock's 52-week range extends from a low of $22.71 to a high of $50.50.

SRRK News

Simply Wall St 12h
Why Scholar Rock Holding Is Up 16.2% After Apitegromab BLA Resubmission With FDA-Aligned Manufacturing

On 31 March 2026, Scholar Rock announced it had resubmitted its Biologics License Application to the FDA for apitegromab in spinal muscular atrophy, now incorpo...

Why Scholar Rock Holding Is Up 16.2% After Apitegromab BLA Resubmission With FDA-Aligned Manufacturing
TipRanks 23h
Scholar Rock Resubmits Apitegromab BLA, Expands Manufacturing Plans

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 1d
What Sent Scholar Rock Holding Stock Higher Today?

Scholar Rock Holding (SRRK) stock soared on Tuesday after the biopharmaceutical company announced it has resubmitted the Biologics License Application (BLA) for...

Analyst ratings

100%

of 16 ratings
Buy
100%
Hold
0%
Sell
0%

More SRRK News

TipRanks 1d
Scholar Rock resubmits BLA to FDA for apitegromab

Scholar Rock (SRRK) announced it has resubmitted the Biologics License Application, BLA, for apitegromab for the treatment of children and adults with Spinal Mu...

Nasdaq 6d
Scholar Rock Holding Price Target Increased by 10.59% to 56.81

The average one-year price target for Scholar Rock Holding (NasdaqGS:SRRK) has been revised to $56.81 / share. This is an increase of 10.59% from the prior esti...

Scholar Rock Holding Price Target Increased by 10.59% to 56.81

People also own

Based on the portfolios of people who own SRRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.